
ePT--the Electronic Newsletter of Pharmaceutical Technology
Baxter Wins Contract to Develop Cell-Based H5N1 Vaccine

ePT--the Electronic Newsletter of Pharmaceutical Technology
Baxter Wins Contract to Develop Cell-Based H5N1 Vaccine

ePT--the Electronic Newsletter of Pharmaceutical Technology
Cambrex (East Rutherford, NJ) to produce Geron (Menlo Park, CA) telomerase anti-cancer vaccine. Generex (Toronto, ON.) files IND for synthetic vaccine to stimulate cell-mediated immunity to avian influenza. Dow Agrosciences (Indianapolis, IN) wins USDA approval for veterinary vaccine, the first manufactured via plant cell culture. G-8 nations pledge billons for vaccine production.

ePT--the Electronic Newsletter of Pharmaceutical Technology
Merck wins approval for rotavirus vaccine as Sanofi ships investigational H5N1 vaccine to NIH and CDC explores new flue diagnostics and novel vaccine-production technology.

ePT--the Electronic Newsletter of Pharmaceutical Technology
Dow AgroSciences Receives Regulatory Approval for Plant-Made Vaccine

ePT--the Electronic Newsletter of Pharmaceutical Technology
Cell-Grown Vaccine Protects Against Avian Flu Virus

ePT--the Electronic Newsletter of Pharmaceutical Technology
Sanofi Pasteur and BD Team Up to Produce Microneedle Vaccines

ePT--the Electronic Newsletter of Pharmaceutical Technology
SEC Loosens Revenue-Recognition Rules for Vaccine Stockpile Participants

ePT--the Electronic Newsletter of Pharmaceutical Technology
NIAID Boosts Vaccine Innovation but Draws Controversy

ePT--the Electronic Newsletter of Pharmaceutical Technology
Adjuvant for HPV Vaccine Enhances Immune Response Levels

Genecor Wins Vaccine-Development Contract

ePT--the Electronic Newsletter of Pharmaceutical Technology
FDA Calls Chiron Facility Acceptable; GSK Gets Green Light For Flu Vaccine

ePT--the Electronic Newsletter of Pharmaceutical Technology
Bavarian Nordic Sues Acambis for Patent Infringement

Acambis and Bavarian Nordic Vie for Smallpox Vaccine Contract

GSK Releases Flu Vaccine Production Strategies

US Government Orders 2M Doses of Avian Flu Vaccine

Chiron Cuts Supply of Flu Vaccines Made in Germany; Liverpool Plant Under Inspection

Vaccine developers are using novel drug delivery methods that offer advantages over traditional techniques such as improved immunogenicity, better stability, specific control over antigen release, and a wider pool of targeted diseases.

Vaccine developers are wrking on new drug delivery systems that offer improved immune responses, better stability, and a wider pool of targeted diseases.

Crucell and NIH Sign Ebola Vaccine Manufacturing Contract

"Stable Liquid" Technology Permits Heptavalent Vaccine Against Botulism

UK MHRA Okays Chiron Flu Vaccine Plant; FDA Approval Still to Come

CBER Draft Guidance for Spore-Formers and Plasmid Vaccines

MHRA to Reinspect Chiron Flu Vaccine Plant

Engineered Oilbodies Produce Vaccines and Adjuvants

Engineered Oilbodies Produce Vaccines and Adjuvants